{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"57.5","value":"22.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"100"}],"units":"Participants"}],"title":"Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"80.2","value":"27.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"86"}],"units":"Participants"}],"title":"Day 29"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"89.4","value":"27.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"}],"units":"Participants"}],"title":"Day 43"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"130.4","value":"29.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"}],"units":"Participants"}],"title":"Day 85"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"65.6","value":"37.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"}],"units":"Participants"}],"title":"Day 127"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"60.3","value":"45.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"title":"Day 169"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"53.0","value":"39.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"}],"units":"Participants"}],"title":"Day 253"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"37.3","value":"39.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"title":"Day 337"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.3","value":"43.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"title":"Day 421"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.4","value":"41.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"title":"Day 505"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.1","value":"57.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Day 589"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.4","value":"44.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"title":"Day 673"}],"denoms":[{"counts":[{"groupId":"OG000","value":"116"}],"units":"Participants"}],"description":"Minimum serum post-dose (Ctrough) concentration of avelumab was reported.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received Avelumab as first-line treatment for metastatic or distally recurrent MCC at a dose of 10 mg/kg as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.","id":"OG000","title":"Part B: Avelumab"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK Analysis Set included all participants who received at least 1 dose of avelumab, and provided at least 1 measurable post-dose concentration. Here \"Number analyzed\" signifies those participants who were evaluable at specified time-point for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Day 15, Day 29, Day 43, Day 85, Day 127, Day 169, Day 253, Day 337, Day 421, Day 505, Day 589, Day 673","title":"Part B: Minimum Serum Post-dose (Ctrough) Concentration of Aveluamb","type":"SECONDARY","unitOfMeasure":"Microgram per milliliter"}